Literature DB >> 2792076

Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule.

B Bogen1, J D Lambris.   

Abstract

We have defined the minimum length of a synthetic peptide which can activate I-Ed-restricted BALB/c T cell clones specific for a mutated self-antigen: an idiotope on the syngeneic lambda 2315 immunoglobulin light chain. A peptide comprising residues 91-101 of the lambda 2315 sequence had full stimulatory potency. Surprisingly, a peptide analogue in which His97 was deleted was almost fully active. Truncated, deleted or substituted peptide analogues did not distinguish between seven T cell clones that use different alpha/beta T cell receptors. The 91-101 region in the lambda 2315 light chain does not form an amphipathic helix even though such a helix has been suggested to be important for T cell epitopes. Further, a motif proposed by Rothbard and Taylor as being common to T cell immunogenic peptides is not necessary for the lambda 2315 idiotypic peptide. Comparison with seven other I-Ed-restricted peptides revealed that the peptides are generally positively charged and have two basic amino acids clustered around the centre. On the basis of a model of the class II molecule peptide binding site, we suggest that these positively charged residues may interact with the negatively charged residues at positions 114(Glu) and 155(Asp) of the E beta d chain.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2792076      PMCID: PMC401055          DOI: 10.1002/j.1460-2075.1989.tb03599.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  34 in total

1.  B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells.

Authors:  S Weiss; B Bogen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

2.  T-immunogenic peptides are constituted of rare sequence patterns. Use in the identification of T epitopes in the human immunodeficiency virus gag protein.

Authors:  J M Claverie; P Kourilsky; P Langlade-Demoyen; A Chalufour-Prochnicka; G Dadaglio; F Tekaia; F Plata; L Bougueleret
Journal:  Eur J Immunol       Date:  1988-10       Impact factor: 5.532

3.  Sequence of a mouse germ-line gene for a variable region of an immunoglobulin light chain.

Authors:  S Tonegawa; A M Maxam; R Tizard; O Bernard; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

4.  Somatic variants of murine immunoglobulin lambda light chains.

Authors:  A L Bothwell; M Paskind; M Reth; T Imanishi-Kari; K Rajewsky; D Baltimore
Journal:  Nature       Date:  1982-07-22       Impact factor: 49.962

5.  Structural alterations in J regions of mouse immunoglobulin lambda genes are associated with differential gene expression.

Authors:  J Miller; E Selsing; U Storb
Journal:  Nature       Date:  1982-02-04       Impact factor: 49.962

6.  DNA sequences of the joining regions of mouse lambda light chain immunoglobulin genes.

Authors:  B Blomberg; S Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

7.  Myeloma proteins as tumor-specific transplantation antigens.

Authors:  R G Lynch; R J Graff; S Sirisinha; E S Simms; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205

8.  Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins.

Authors:  S Sirisinha; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1971-12       Impact factor: 11.205

9.  Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes.

Authors:  C A Janeway; N Sakato; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

10.  The complete nucleotide sequence of the I-E alpha d immune response gene.

Authors:  J J Hyldig-Nielsen; L Schenning; U Hammerling; E Widmark; E Heldin; P Lind; B Servenius; T Lund; R Flavell; J S Lee; J Trowsdale; P H Schreier; F Zablitzky; D Larhammar; P A Peterson; L Rask
Journal:  Nucleic Acids Res       Date:  1983-08-11       Impact factor: 16.971

View more
  19 in total

1.  DNA immunization with HBsAg-based particles expressing a B cell epitope of amyloid β-peptide attenuates disease progression and prolongs survival in a mouse model of Alzheimer's disease.

Authors:  Purevdorj B Olkhanud; Mohammed Mughal; Koichi Ayukawa; Enkhzol Malchinkhuu; Monica Bodogai; Neil Feldman; Sarah Rothman; Jong-Hwan Lee; Srinivasulu Chigurupati; Eitan Okun; Kunio Nagashima; Mark P Mattson; Arya Biragyn
Journal:  Vaccine       Date:  2012-01-14       Impact factor: 3.641

2.  Peptide phage libraries can be an efficient tool for identifying antibody ligands for polyclonal antisera.

Authors:  A Dybwad; B Bogen; J B Natvig; O Førre; M Sioud
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

3.  Enhancement of peptide antigen presentation by a second peptide.

Authors:  A I de Kroon; H M McConnell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

4.  Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4- Tregs, regulate effector T cells using FasL.

Authors:  Dolgor Baatar; Purevdorj Olkhanud; Kenya Sumitomo; Dennis Taub; Ronald Gress; Arya Biragyn
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

5.  Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody.

Authors:  A Waisman; P J Ruiz; E Israeli; E Eilat; S Könen-Waisman; H Zinger; M Dayan; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

6.  Periplasmic expression of soluble single chain T cell receptors is rescued by the chaperone FkpA.

Authors:  Kristin S Gunnarsen; Elin Lunde; Per E Kristiansen; Bjarne Bogen; Inger Sandlie; Geir Å Løset
Journal:  BMC Biotechnol       Date:  2010-02-03       Impact factor: 2.563

7.  Sperm-derived SPANX-B is a clinically relevant tumor antigen that is expressed in human tumors and readily recognized by human CD4+ and CD8+ T cells.

Authors:  Giovanni Almanzar; Purevdorj B Olkhanud; Monica Bodogai; Chiara Dell'agnola; Dolgor Baatar; Stephen M Hewitt; Claudio Ghimenton; Mohan K Tummala; Ashani T Weeraratna; Keith Sean Hoek; Natalay Kouprina; Vladimir Larionov; Arya Biragyn
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

8.  Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity.

Authors:  Arya Biragyn; Roberta Schiavo; Purevdorj Olkhanud; Kenya Sumitomo; Alan King; Megan McCain; Fred E Indig; Giovanni Almanzar; Dolgor Baatar
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

9.  Heterodimeric barnase-barstar vaccine molecules: influence of one versus two targeting units specific for antigen presenting cells.

Authors:  Heidi Cecilie Larsen Spång; Ranveig Braathen; Bjarne Bogen
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

10.  Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells.

Authors:  Agnete B Fredriksen; Inger Sandlie; Bjarne Bogen
Journal:  Front Oncol       Date:  2012-10-30       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.